PMID: 10211147Apr 22, 1999

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

The British Journal of Psychiatry : the Journal of Mental Science
C M BeasleyGary D Tollefson

Abstract

Tardive dyskinesia is important in the side-effect profile of antipsychotic medication. The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years. Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD), it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated. The relative risk of tardive dyskinesia for the overall follow up period for haloperidol (n = 522) v. olanzapine (n = 1192) was 2.66 (95% CI = 1.50-4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n = 513) and 7.45% with haloperidol (n = 114). The relative risk throughout this follow-up period was 11.37 (95% CI = 2.21-58.60). Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.

References

Jan 1, 1991·European Archives of Psychiatry and Clinical Neuroscience·Toshiya InadaY Masuda
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
May 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G GardosD E Casey
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1981·Acta Psychiatrica Scandinavica. Supplementum·A C Gibson
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, John M Kane
Feb 1, 1983·The American Journal of Psychiatry·G Gardos, J O Cole
Jun 1, 1984·Psychosomatics·R Yassa, V Nair
Aug 1, 1982·Clinical Physiology·M Lye, E B Faragher
Jun 1, 1995·The Journal of Nervous and Mental Disease·C H MillerW W Fleischhacker
Nov 15, 1993·Biological Psychiatry·W W FleischhackerM A Richardson
Apr 1, 1996·Archives of General Psychiatry·M H ChakosJeffrey A Lieberman
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS H Hamilton
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen

Citations

Nov 4, 2006·Der Nervenarzt·W W Fleischhacker, W Hummer
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Martin DossenbachOlanzapine HGCH Study Group
Dec 24, 2003·Journal of Psychiatric Research·Dilip V Jeste, Christian R Dolder
Aug 11, 2000·General Hospital Psychiatry·A I GreenG Blackburn
Jun 12, 2003·Journal of Affective Disorders·Maria Carolina HardoyMarcello Nardini
Aug 22, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasElias Tzavellas
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Helen Rosengarten, David Quartermain
Aug 2, 2001·Schizophrenia Research·T H McGlashan
Apr 6, 2004·Schizophrenia Research·Beata J Havaki-KontaxakiGeorge N Christodoulou
Jun 8, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·Pierre-Michel LlorcaChristophe Lançon
Mar 7, 2006·Nature Reviews. Drug Discovery·T Scott StroupJeffrey A Lieberman
Feb 25, 2009·The Pharmacogenomics Journal·C C ZaiJames L Kennedy
Nov 25, 2003·Psychiatry and Clinical Neurosciences·I-ning YehHsing-Cheng Liu
Jan 22, 2002·Clinical Neuropharmacology·O Rascol, N Fabre
Aug 15, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·R P MaloneM A Delaney
Nov 26, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·S W WoodsT H McGlashan
Feb 3, 2007·Clinical Neuropharmacology·Hima B PalakurthiStuart Kaplan
Feb 7, 2007·Current Opinion in Psychiatry·Gary Remington
Jun 16, 2007·Neuropsychobiology·M D OhlmeierU Schneider
Apr 7, 2011·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yui YamamotoKohji Fukunaga
Aug 1, 2007·Healthcare Policy = Politiques De Santé·Daria O'ReillyPatrick Parfrey
Jun 22, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David M GardnerPaul Waraich
Dec 10, 2003·CNS Drugs·Robin EmsleySusan J van Rensburg
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Jul 1, 2007·Indian Journal of Psychiatry·V N VahiaP Deotale
Nov 5, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Chintan ShahAnita Kablinger
Mar 17, 2004·Biological Psychiatry·Cristina GrandeRosario Moratalla
Mar 22, 2006·Psychopharmacology·Sanneke A M van VlietIngrid H C H M Philippens
Jan 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·V L Bella, F Piccoli
Jun 19, 2012·General Hospital Psychiatry·John LallyElizabeth Walsh
Apr 24, 2013·Journal of Clinical Psychopharmacology·Daniel M BlumbergerBarnett S Meyers
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
Jan 19, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Huijie LiQi-Yong Gong
Sep 8, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Sierra PeñaJoseph Jankovic
Aug 7, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·James T TeoKailash Bhatia
Apr 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vaios PeritogiannisVenetsanos Mavreas
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·R A RosenheckJeffrey A Lieberman
Mar 1, 2005·The Psychiatric Clinics of North America·Perminder S Sachdev
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Barrat Luft, David Taylor
May 13, 2014·Asian Journal of Psychiatry·Rashmin M AchaliaOm Prakash
Sep 9, 2006·The International Journal of Neuropsychopharmacology·Clement C ZaiJames L Kennedy
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Dec 19, 2001·International Journal of Geriatric Psychiatry·J S KennedyA Breier
Jan 11, 2017·Journal of Psychiatric Practice·Dinesh SangroulaDavid A Kahn
Jan 5, 2002·Journal of Psychopharmacology·P OosthuizenN Keyter
Jul 11, 2014·Journal of Geriatric Psychiatry and Neurology·Bruce J KinonVirginia Stauffer
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Aug 9, 2002·Headache·Stephen D SilbersteinTodd D Rozen
May 29, 2001·International Journal of Geriatric Psychiatry·H MorgensternS W Woods
Apr 23, 2005·The Cochrane Database of Systematic Reviews·L DugganS Indran
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Maren CarbonChristoph U Correll
Mar 18, 2003·Journal of Clinical Psychopharmacology·Juan Antonio CarrilloJulio Benítez
May 17, 2006·Journal of Clinical Psychopharmacology·Michael LindenJoerg Czekalla
Feb 22, 2008·Psychiatry and Clinical Neurosciences·Nobutomo YamamotoToshiya Inada
Mar 16, 2001·Expert Opinion on Pharmacotherapy·B C Lund, P J Perry
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
Dec 24, 2005·Harvard Review of Psychiatry·Dilip V JesteCarl Salzman
Jun 22, 2006·Harvard Review of Psychiatry·Arshia A Shirzadi, S Nassir Ghaemi
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·R A Rosenheck
May 2, 2000·The British Journal of Psychiatry : the Journal of Mental Science·S W Woods
Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller
Dec 16, 2016·The Cochrane Database of Systematic Reviews·Ranganath D RattehalliStephanie Sampson
Aug 13, 2002·Journal of Clinical Psychopharmacology·Franco Benazzi
Oct 3, 2002·The Journal of Nervous and Mental Disease·Daniel J Safer
Feb 13, 2003·Acta Psychiatrica Scandinavica·J M HaroSOHO Study Group
Jun 17, 2011·The Cochrane Database of Systematic Reviews·John BolaHaluk Soydan
Dec 29, 2000·The Australian and New Zealand Journal of Psychiatry·S V CattsD M Draganic
Aug 2, 2005·The British Journal of Psychiatry. Supplement·Gary Remington
Jan 11, 2020·Frontiers in Pharmacology·Francesco De PretisBarbara Osimani
Apr 26, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·P TurroneS Silvestri
Aug 2, 2005·The British Journal of Psychiatry. Supplement·T H McGlashan
Jul 9, 2020·Journal of Clinical Psychopharmacology·Stanley N CaroffE Cabrina Campbell
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Sep 5, 2006·CNS Spectrums·S W WoodsT H McGlashan
Aug 16, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rahul ManchandaNicola Banks
Jul 27, 2004·CNS Spectrums·Gary Remington, Chekkera Shammi

Related Concepts

Zyprexa
Benzodiazepines
Double-Blind Method
Dyskinesia, Medication-Induced
Haldol
Pirenzepin von ct
Schizophrenia
Antipsychotic Effect
Survival Analysis

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here